Psychedelic substances like psilocybin, MDMA, and ketamine are increasingly used in research and clinical medicine.
By their very nature, these substances put patients in a vulnerable position. The altered states of consciousness produced by psychedelics can promote insight and healing. However, unscrupulous practitioners can also exploit patients when they are under the influence of these substances. Reports of abuse by licensed and underground psychedelic facilitators highlight these concerns.
On November 18th, 2021, Harvard T.H. Chan School of Public Health hosted a panel with Harris Bricken attorney, Mason Marks in addition to ethicists, health care providers, and academic researchers. The panel discussed these risks and broader concerns regarding ethics in psychedelic therapy and research.
Need Help With Psychedelics Law?